This segment focuses on the development and commercialization of the KidneyIntelX platform, an AI-enabled in vitro diagnostic solution for kidney diseases. Research and development activities include refining the AI algorithm, validating blood-based biomarkers, and integrating patient data from electronic health records. The platform utilizes machine learning and data analytics to generate a unique patient risk score, aiding in early diagnosis, prognosis, and patient stratification for clinical trials. The therapeutic area is nephrology, specifically addressing chronic kidney disease (CKD) and diabetic kidney disease (DKD). The platform aims to improve patient outcomes by enabling earlier interventions and personalized treatment plans. Market positioning is as a leader in AI-driven kidney diagnostics, with a competitive advantage in its ability to integrate multiple data inputs. Future opportunities include expanding the platform's capabilities, securing regulatory approvals, and broadening market access. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical validation studies. Partnerships include collaborations with healthcare providers like Atrium Health and research institutions like the University of Utah.